The changing paradigm in EUS-guided tissue acquisition.
The diagnostic performance of endoscopic ultrasound-guided fine-needle aspiration is strongly dependent on the availability of an onsite cytopathologist. The diagnosis of some rare tumors may require ancillary testing for which a histologic core biopsy is required. There is increasing interest in evaluating core tissue for molecular markers that may serve as prognostic predictors and targets for focused chemotherapy in patients with cancer. If core tissue can be procured efficiently and reliably at endoscopic ultrasound, this will eliminate the need for an onsite cytopathologist, accurately diagnose tumors that are occasionally missed by fine-needle aspiration cytology, and enable the assessment for molecular markers.